Christopher Bechtel is listed as a director on 1 SEC Form D filing by 1 issuer in May 2015: Supreme Pharmaceuticals Inc. (Toronto, Ontario, Canada (as filed: A6) — pharmaceuticals — 2015; $1.21M reported sold to 27 investors).
What this means One deal on file with the SEC, filed May 2015. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Allan Levien (1 shared filing), Cailin Gehlsen (1 shared filing), John Fowler (1 shared filing) and Peter Herburger (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Christopher. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 1 public filing for Christopher Bechtel and found 1 difference, 1 worth asking the sponsor about: 4 paid sellers are listed without a CRD number.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.